Who are Dalcetrapib (RO4607381)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Monotherapy obicetrapib, Placebo anacetrapib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/dalcetrapib-ro4607381.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dalcetrapib (RO4607381) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dalcetrapib (RO4607381) (Dalcetrapib (RO4607381)) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CETP inhibitor. Area: Cardiovascular.

phase 3 CETP inhibitor CETP (Cholesteryl ester transfer protein) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Dalcetrapib (RO4607381) (Dalcetrapib (RO4607381)) — Hoffmann-La Roche. Dalcetrapib inhibits cholesteryl ester transfer protein (CETP) to increase HDL cholesterol and reduce LDL cholesterol levels.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Dalcetrapib (RO4607381) TARGET	Dalcetrapib (RO4607381)	Hoffmann-La Roche	phase 3	CETP inhibitor	CETP (Cholesteryl ester transfer protein)
Monotherapy obicetrapib	Monotherapy obicetrapib	NewAmsterdam Pharma	phase 3	CETP inhibitor	CETP (cholesterol ester transfer protein)
Placebo anacetrapib	Placebo anacetrapib	University of Oxford	phase 3	CETP inhibitor	cholesterol ester transfer protein (CETP)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CETP inhibitor class)

Hoffmann-La Roche · 1 drug in this class
NewAmsterdam Pharma · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Dalcetrapib (RO4607381) — Competitive Intelligence Brief. https://druglandscape.com/ci/dalcetrapib-ro4607381. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing